Publication
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (16)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 16
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugAlpelisibcivic_curation1.00
- drugFulvestrantcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA C420Rcivic_curation1.00
- variantPIK3CA E542Kcivic_curation1.00
- variantPIK3CA E545Acivic_curation1.00
- variantPIK3CA E545Dcivic_curation1.00
- variantPIK3CA E545Gcivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
- variantPIK3CA H1047Lcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
- variantPIK3CA H1047Ycivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPIK3CA Q546Ecivic_curation1.00
- variantPIK3CA Q546Rcivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31091374
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA C420R1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11275In this randomized, phase III trial, 572 patients with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously underwent randomization, including 341 patients w… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA E542K1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID7315In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA E545A + PIK3CA E545D + PIK3CA E545G + PIK3CA E545K1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID7468In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA H1047L + PIK3CA H1047R + PIK3CA H1047Y1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7318In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA Mutation2 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7313In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | rejected | EID7317In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA Q546E + PIK3CA Q546R1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7316In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |